<DOC>
	<DOCNO>NCT01630811</DOCNO>
	<brief_summary>Primary : Demonstrate reduce frequency intensity maladaptive behavior measure Aberrant Behavior Checklist ( ABC ) Irritability subscale subject give Nuedexta 8 week subject give placebo . Secondary : Demonstrate trend towards reduce aggressive behavior measure Overt Aggression Scale ( OAS ) .</brief_summary>
	<brief_title>Nuedexta Treatment Adults With Autism</brief_title>
	<detailed_description>This randomize placebo-controlled crossover study . The parent , neuropsychologists , clinical research coordinator ( CRC ) PI blind whether subject placebo Nuedexta . Nuedexta give daily 7 day . If well-tolerated , give every 12 hour next 7 week . Patients may also remain once-daily dose desire . The study last 44 week . This include 20 week study enrollment , 8 week treatment/placebo , 4 week washout , second 8 week-period treatment/placebo follow 4 week washout . Subjects randomize 8 week Nuedexta/placebo . After 8 week follow-up visit , 4 week washout period . At week 12 ( second baseline ) , group crossover another 8 week Nuedexta/placebo . Study endpoint measure group week 8 , 12 , 20 . A final study visit occur week 24 .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>1 . 18 60 year age 2 . Have collateral informant attend visit answer questionnaires pertain participant behavior 3 . Diagnosis autistic spectrum disorder base Diagnostic Statistical Manual , 4th edition , Text Revised ( DSMIVTR ) criterion , developmental history , Autism Diagnostic Observation Schedule ( ADOS ) ; confirm diagnosis autism childhood similar method 4 . Capable give informed consent , legal guardian capable give consent subject 's behalf ; patient able assent participate 5 . Mood issue frontal lobe type perseveration issue 6 . No medication change within 30 day use new medication course study except nonrelated condition approve investigator 1 . Clinically uncontrolled epilepsy 2 . Cardiovascular condition include cardiac structural malformation heart failure , prolong QT interval , history torsades de pointes , AV block 3 . Known genetic disorder , fragile x , know brain structural abnormality , cerebral palsy , head injury , brain tumor 4 . Known allergy either dextromethorphan quinidine 5 . Concurrent recent use Monoamine oxidase inhibitor ( MAOI ) antidepressants pt Nuedexta 6 . Concurrent use lamotrigine felbamate NMDA agonists antagonists 7 . Thrombocytopenia , hepatitis , bone marrow depression lupuslike syndrome 8 . Pregnancy sexually active female childbearing potential must reliable form contraception 9 . Other clinically significant abnormality physical , neurological , laboratory , vital sign , could compromise study detrimental subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Adults</keyword>
</DOC>